KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Receivables (2020 - 2025)

Ginkgo Bioworks Holdings' Change in Receivables history spans 6 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 232.12% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.5 million, down 68.83%, while the annual FY2025 figure was $1.5 million, 68.83% down from the prior year.
  • Change in Receivables reached $1.8 million in Q4 2025 per DNA's latest filing, up from -$757000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $85.4 million in Q4 2021 to a low of -$59.1 million in Q3 2022.
  • Average Change in Receivables over 5 years is $760000.0, with a median of -$115500.0 recorded in 2023.
  • Peak YoY movement for Change in Receivables: crashed 533.87% in 2023, then surged 1187.07% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $85.4 million in 2021, then plummeted by 140.39% to -$34.5 million in 2022, then rose by 16.24% to -$28.9 million in 2023, then surged by 95.24% to -$1.4 million in 2024, then soared by 232.12% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Change in Receivables are $1.8 million (Q4 2025), -$757000.0 (Q3 2025), and -$4.3 million (Q2 2025).